A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.
Park, Won
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. [electronic resource] - Annals of the rheumatic diseases Oct 2013 - 1605-12 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1468-2060
10.1136/annrheumdis-2012-203091 doi
Adolescent
Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibody Formation
Antirheumatic Agents--adverse effects
Double-Blind Method
Female
Humans
Immunoglobulin G--adverse effects
Infliximab
Male
Middle Aged
Prospective Studies
Severity of Illness Index
Spondylitis, Ankylosing--blood
Treatment Outcome
Young Adult
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. [electronic resource] - Annals of the rheumatic diseases Oct 2013 - 1605-12 p. digital
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1468-2060
10.1136/annrheumdis-2012-203091 doi
Adolescent
Adult
Aged
Antibodies, Monoclonal--adverse effects
Antibody Formation
Antirheumatic Agents--adverse effects
Double-Blind Method
Female
Humans
Immunoglobulin G--adverse effects
Infliximab
Male
Middle Aged
Prospective Studies
Severity of Illness Index
Spondylitis, Ankylosing--blood
Treatment Outcome
Young Adult